The combination of αPD-L1 and RdB/IL12/GMCSF, RdB/IL12/shVEGF, RdB/IL12/DCN, RdB/IL12/GMCSF-TK, or RdB/IL12/GMCSF-RLX also resulted in 66.7%, 83.3%, 50.0%, 50.0%, and 83.3% tumor regression on day 50 post initial treatment, respectively (Table 1). The gene discussed is CSF2; the disease is neoplasm.